Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06725810 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Correction of Anemia With Enarodustat in Non-dialysis Dependent Chronic Kidney Disease

Study acronym: CANNON
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruitingv2 Show 6 more changesShow less
    • Start date changed from estimate of Dec 1, 2024 to Mar 27, 2025
    • Interventions: enadustat (Drug) to Enarodustat (Drug)
    • Secondary endpoints: details revised at 2 of 6 entries
    • Study description expanded, about 194 words
    • Site details revised
    • Collaborators shortened, about 6 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The CANNON trial is a prospective, open-label, randomized, multicenter study designed to investigate rational hemoglobin target value in patients with anemia of non-dialysis chronic kidney disease treated with enarodustat. Eligible patients are randomly assigned 1:1 to the high-hemoglobin target group （hemoglobin of 13 g/dl）and low-hemoglobin target group （hemoglobin of 11 g/dl）and administered with enarodustat to achieve and maintain target hemoglobin over 96 weeks. The first primary endpoint was the difference of mean change in 36-Item Short Form Health Survey at week 24. The second primary endpoint was safety endpoints included time to major adverse cardiovascular + event (MACE+; all-cause mortality, myocardial infarction, stroke, and congestive heart failure requiring hospitalization) during 96 weeks.
Trial Details
NCT Number NCT06725810
Lead Sponsor Shanghai Zhongshan Hospital
Conditions
(from sponsor)		 Chronic Kidney Disease Associated Anemia
Related terms Anemia, Renal Insufficiency, Chronic
Enrollment 1,670 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov